Predictive Biosciences adds diagnostics vet to board

February 2, 2010 by MassDevice staff

Predictive Biosciences tapped veteran diagnostics industry executive Kim Blickenstaff, president and CEO of insulin pump developer Tandem Diabetes Care Inc., for its board of directors.

The Lexington, Mass-based cancer diagnostics developer said Blickenstaff's expertise will come in handy as it readies to bring a non-invasive molecular diagnostic for bladder cancer to market via a recent acquisition.

Predictive bought molecular diagnostics firm OncoDiagnostic Laboratory for an undisclosed amount earlier this month, issuing $1.4 million in stock as part of the deal. The company said Blickenstaff's appointment to its board plays into its plans for Cleveland-based ODL.

Blickenstaff was co-founder, chairman and CEO of Biosite Inc. until it was bought for $1.8 billion by Inverness Medical Innovations Inc. (NYSE:IMA) in 2007. His resumé includes stints at Hybritech Inc., Baxter Healthcare (NYSE:BAX) and tenures on the boards of SenoRx (NSDQ:SENO) and MediVation Inc. (NSDQ:MDVN).

Permalink